Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Astragaloside IV attenuates inflammatory response mediated by NLRP‐3/calpain‐1 is involved in the development of pulmonary hypertension
Yang Sun, Meili Lü, Tai-Ran Sun, et al.
Journal of Cellular and Molecular Medicine (2020) Vol. 25, Iss. 1, pp. 586-590
Open Access | Times Cited: 31

Showing 1-25 of 31 citing articles:

Pharmacological Inhibition of the Nod-Like Receptor Family Pyrin Domain Containing 3 Inflammasome with MCC950
Sarah E. Corcoran, Reena Halai, Matthew A. Cooper
Pharmacological Reviews (2021) Vol. 73, Iss. 3, pp. 968-1000
Open Access | Times Cited: 120
Astragaloside IV ameliorate acute alcohol-induced liver injury in mice via modulating gut microbiota and regulating NLRP3/caspase-1 signaling pathway
Shangong Wu, Fei Wen, Xiangbin Zhong, et al.
Annals of Medicine (2023) Vol. 55, Iss. 1
Open Access | Times Cited: 29
Review on the protective mechanism of astragaloside IV against cardiovascular diseases
Chunkun Yang, Qingquan Pan, Kui Ji, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 21
Dapagliflozin, sildenafil and their combination in monocrotaline-induced pulmonary arterial hypertension
Yi Tang, Siyuan Tan, Minqi Li, et al.
BMC Pulmonary Medicine (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 25
Traditional Herbal Medicine Discovery for the Treatment and Prevention of Pulmonary Arterial Hypertension
Zhifeng Xue, Yixuan Li, Mengen Zhou, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 29
Cell Death in Pulmonary Arterial Hypertension
Xia Li, JunLan Tan, JiaJing Wan, et al.
International Journal of Medical Sciences (2024) Vol. 21, Iss. 10, pp. 1840-1851
Open Access | Times Cited: 4
Recent pharmacological advances in the treatment of cardiovascular events with Astragaloside IV
Zehui Xu, Houle Zhou, Yihan Zhang, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 168, pp. 115752-115752
Open Access | Times Cited: 10
Astragaloside IV improves pulmonary arterial hypertension by increasing the expression of CCN1 and activating the ERK1/2 pathway
Yu Liu, Bailin Tang, Meili Lü, et al.
Journal of Cellular and Molecular Medicine (2023) Vol. 27, Iss. 5, pp. 622-633
Open Access | Times Cited: 8
SGLT2 inhibitors as a potential therapeutic option for pulmonary hypertension: mechanisms and clinical perspectives
Jiang-Shan Tan, Yixiao Wei, Lingtao Chong, et al.
Critical Reviews in Clinical Laboratory Sciences (2024), pp. 1-17
Closed Access | Times Cited: 3
A new perspective on targeting pulmonary arterial hypertension: Programmed cell death pathways (Autophagy, Pyroptosis, Ferroptosis)
Qingliang Ge, Tianqing Zhang, Jinpu Yu, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 181, pp. 117706-117706
Open Access | Times Cited: 3
LncRNA HOXA-AS3 Promotes the Progression of Pulmonary Arterial Hypertension through Mediation of miR-675-3p/PDE5A Axis
Zhongkui Li, Lufang Gao, Xian Zhu, et al.
Biochemical Genetics (2021) Vol. 59, Iss. 5, pp. 1158-1172
Closed Access | Times Cited: 19
Qiqilian ameliorates vascular endothelial dysfunction by inhibiting NLRP3-ASC inflammasome activation in vivo and in vitro
Yuan Luo, Tan Zhen-yuan, Yun Ye, et al.
Pharmaceutical Biology (2023) Vol. 61, Iss. 1, pp. 815-824
Open Access | Times Cited: 7
Safflower Alleviates Pulmonary Arterial Hypertension by Inactivating NLRP3: A Combined Approach of Network Pharmacology and Experimental Verification
Shibiao Ding, Jinyu Cui, Luning Yan, et al.
The Clinical Respiratory Journal (2024) Vol. 18, Iss. 8
Open Access | Times Cited: 2
Saponins as potential novel NLRP3 inflammasome inhibitors for inflammatory disorders
Jiamei Tang, Yaxiao Liu, Ying Wu, et al.
Archives of Pharmacal Research (2024) Vol. 47, Iss. 10-11, pp. 757-792
Closed Access | Times Cited: 2
Ginsenoside Rg1 attenuates diabetic vascular endothelial dysfunction by inhibiting the calpain-1/ROS/PKC-β axis
Meili Lu, Fang Zhao, Chenyang Ran, et al.
Life Sciences (2023) Vol. 329, pp. 121972-121972
Open Access | Times Cited: 6
A peripheral system disease—Pulmonary hypertension
Yang Sun, Chen Chen, Yan Qian, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 175, pp. 116787-116787
Open Access | Times Cited: 2
Astragaloside IV ameliorates pulmonary vascular remodeling in hypoxia-induced pulmonary hypertension by restraining the T follicular helper cell response and expanding T follicular regulatory cell response
Cheng Li, Hao Zhu, Shaoze Zhang, et al.
Phytomedicine (2022) Vol. 102, pp. 154171-154171
Closed Access | Times Cited: 10
TPN171H alleviates pulmonary hypertension via inhibiting inflammation in hypoxia and monocrotaline-induced rats
Congke Zhao, Liqing Hu, Xiangrong He, et al.
Vascular Pharmacology (2022) Vol. 145, pp. 107017-107017
Closed Access | Times Cited: 10
The BCL2/BAX/ROS pathway is involved in the inhibitory effect of astragaloside IV on pyroptosis in human umbilical vein endothelial cells
Yi Su, Xin Yin, Xin Huang, et al.
Pharmaceutical Biology (2022) Vol. 60, Iss. 1, pp. 1812-1818
Open Access | Times Cited: 10
Natural Products for the Treatment of Pulmonary Hypertension: Mechanism, Progress, and Future Opportunities
Zuomei Zeng, Xinyue Wang, Lidan Cui, et al.
Current Issues in Molecular Biology (2023) Vol. 45, Iss. 3, pp. 2351-2371
Open Access | Times Cited: 4
Astragaloside IV Protects against Shear Stress-Induced Glycocalyx Damage and Alleviates Abdominal Aortic Aneurysm by Regulating miR-17-3p/Syndecan-1
Guojian Li, Qionghui Yang, Kaikai Luo, et al.
Analytical Cellular Pathology (2024) Vol. 2024, pp. 1-15
Open Access | Times Cited: 1
The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle
Liangzhen Qu, Xueting Duan, Han Chen
ESC Heart Failure (2024)
Open Access | Times Cited: 1
Untapping the Potential of Astragaloside IV in the Battle Against Respiratory Diseases
Junlan Tan, Jian Yi, Xianya Cao, et al.
Drug Design Development and Therapy (2023) Vol. Volume 17, pp. 1963-1978
Open Access | Times Cited: 3
Is telomerase a hidden player? Therapeutic potential of natural telomerase activators against age-related diseases
Gülten Kuru, Göklem Üner, Erdal Bedіr
Phytochemistry Reviews (2022) Vol. 22, Iss. 1, pp. 35-72
Closed Access | Times Cited: 4
Page 1 - Next Page

Scroll to top